Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry

Rutgeerts, 2004, Optimizing anti-TNF treatment in inflammatory bowel disease, Gastroenterology, 126, 1593, 10.1053/j.gastro.2004.02.070

Hanauer, 1996, Drug therapy, N Engl J Med, 334, 841, 10.1056/NEJM199603283341307

Podolsky, 2002, Inflammatory bowel disease, N Engl J Med, 347, 417, 10.1056/NEJMra020831

Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502

Rutgeerts, 2004, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease, Gastroenterology, 126, 402, 10.1053/j.gastro.2003.11.014

Hanauer, 2002, Maintenance infliximab for Crohn’s disease, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4

Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X

Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn’s disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804

Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn’s disease, N Engl J Med, 350, 876, 10.1056/NEJMoa030815

Stuck, 1989, Risk of infectious complication in patients taking glucocorticosteroids, Rev Infect Dis, 11, 954, 10.1093/clinids/11.6.954

Yang, 2002, Corticosteroids in Crohn’s disease, Am J Gastroenterol, 97, 803, 10.1111/j.1572-0241.2002.05596.x

Sandborn, 1996, A review of immune modifier therapy for inflammatory bowel disease, Am J Gastroenterol, 91, 423

Aucott, 1994, Glucocorticoids and infection, Endocrinol Metab Clin North Am, 23, 655, 10.1016/S0889-8529(18)30091-4

Klein, 2001, Infections associated with steroid use, Infect Dis Clin North Am, 15, 423, 10.1016/S0891-5520(05)70154-9

Colombel, 2004, The safety profile of infliximab in patients with Crohn’s disease, Gastroenterology, 126, 19, 10.1053/j.gastro.2003.10.047

Ricart, 2001, Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic, Am J Gastroenterol, 96, 722, 10.1111/j.1572-0241.2001.03612.x

Cohen, 2000, Infliximab in Crohn’s disease, Am J Gastroenterol, 95, 3469, 10.1111/j.1572-0241.2000.03363.x

Farrell, 2000, Clinical experience with infliximab therapy in 100 patients with Crohn’s disease, Am J Gastroenterol, 95, 3490, 10.1111/j.1572-0241.2000.03366.x

Hanauer, 2001, Management of Crohn’s disease in adults, Am J Gastroenterol, 96, 635, 10.1111/j.1572-0241.2001.03671.x

Hosmer, 1998

Ljung, 2004, Infliximab in inflammatory bowel disease, Gut, 53, 849, 10.1136/gut.2003.018515

Jess, 2002, Mortality and causes of death in Crohn’s disease, Gastroenterology, 122, 1808, 10.1053/gast.2002.33632

Loftus, 1998, Crohn’s disease in Olmstead County, Minnesota, 1940-1993, Gastroenterology, 114, 1161, 10.1016/S0016-5085(98)70421-4

Farmer, 1985, Long-term follow-up of patients with Crohn’s disease. Relationship between clinical pattern and prognosis, Gastroenterology, 88, 1818, 10.1016/0016-5085(85)90006-X

Ekbom, 1992, Survival and causes of death in patients with inflammatory-bowel disease, Gastroenterology, 103, 954, 10.1016/0016-5085(92)90029-X

Present, 1989, 6-mercaptopurine in the management of inflammatory bowel disease, Ann Intern Med, 111, 641, 10.7326/0003-4819-111-8-641

Aberra, 2003, Corticosteroids and immunomodulators, Gastroenterology, 125, 320, 10.1016/S0016-5085(03)00883-7

Edwards, 2001, Chronic narcotic use in inflammatory bowel disease patients, J Gastroenterol Hepatol, 16, 1235, 10.1046/j.1440-1746.2001.02468.x

Kaplan, 1988, Narcotic dependence in inflammatory bowel disease, J Clin Gastroenterol, 10, 275, 10.1097/00004836-198806000-00010